Fluralaner

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

The exact feline range is centrally authorised in the EU with current combined official product information and strong indication-specific trials; Georgian registration is shown separately per presentation.

Randomised field and controlled studies show high, sustained efficacy across fleas, ticks and labelled nematodes, including lungworm prevention; the fixed combination is appropriate only when ectoparasite control and another labelled parasite target are needed together.

Generally well tolerated, but transient skin, gastrointestinal and rare neurologic reactions are recognised; young or underweight cats, reproduction, adult heartworm assessment and P-glycoprotein inhibitor combinations require specific precautions.

One whole weight-banded pipette gives broad long-interval coverage, but direct skin placement, prevention of grooming, indication-specific retreatment and pre-treatment parasite-risk assessment are essential.

The exact composition, five strengths, dose table and current Georgian and Costa Rican veterinary authorisations are traceable, but the public clinical dossier is the manufacturer insert; no independent Power Gold assessment report, equivalence study or exact EU/GB/US authorisation was located.

The manufacturer label claims 12-week control of two flea species and R. sanguineus. Randomised studies support the same active, concentration, strengths and 25 mg/kg regimen in the Bravecto reference formulation, but they are sponsor-linked or formulation-transferred and no Power Gold equivalence or outcome study verifies efficacy transfer.

The exact insert identifies uncommon transient gastrointestinal effects and rare seizure/lethargy reports, with epilepsy caution and age/weight limits. Class pharmacovigilance adds tremor and ataxia, while exact-product frequency, repeated-use and independent reproductive safety data remain limited.

One whole palatable chew with food and a 12-week interval is highly workable, with five clear weight bands. Current weighing and confirmation of ingestion are simple, but printed decimal gaps and no above-56-kg combination instruction require strict label boundaries.